A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:September 2012
End Date:July 2017
Contact:Oncogenex Pharmaceuticals
Phone:(425) 686-1500

Use our guide to learn which trials are right for you!

A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

The primary objective of the study is to compare overall survival of patients randomized to
receiving custirsen in combination with docetaxel (Arm A) with patients randomized to
receive docetaxel alone (Arm B).


Inclusion Criteria:

1. Patients must have a histologically or cytologically confirmed, unresectable,
advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC

2. Males or females ≥ 18 years of age at screening.

3. Life expectancy of > 12 weeks from screening, according to the investigator's
assessment.

4. Patients must have received one prior line of platinum-based systemic anticancer
therapy for advanced or metastatic NSCLC. Prior maintenance therapy is allowed and
will be considered as the same line of therapy when continued at the end of a
treatment regimen.

5. Patients must have documented radiological disease progression either during or after
the first-line therapy.

6. Patients must have at least one measurable lesion per RECIST 1.1 criteria.

7. ECOG performance status of 0 or 1 at screening.

8. Have adequate values, bone marrow, renal and liver functions at screening as defined
below:

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

- Platelet count ≥ 100 x 109/L

- Hemoglobin ≥ 9 g/dL

- Serum creatinine ≤ 1.5 x upper limit of normal (ULN)

- Total Bilirubin ≤ 1.0 x ULN (unless elevated secondary to benign conditions such
as Gilbert's disease)

- AST and ALT ≤ 1.5 x ULN

9. Resolution of any toxic effects of prior therapy to Grade ≤1 according to NCI CTCAE,
version 4.0 (exception of alopecia and ≤ Grade 2 peripheral neuropathy).

10. Females of child-bearing potential must have negative serum pregnancy test within 72
hours before randomization.

11. Women of child-bearing potential will practice a highly effective method of birth
control during and for 3 months after the chemotherapy/ custirsen last dose. Men of
reproductive potential who are not surgically sterile must agree to abstain from
sexual activity or use medically accepted and highly effective method of
contraception during and for 6 months after the chemotherapy/custirsen last dose.

12. Patients must be willing and able to give written informed consent prior to any
protocol-specific procedures being performed and comply with the protocol
requirements for the duration of the study.

Exclusion Criteria:

1. Patients treated with any systemic anti-cancer therapy for NSCLC within 21 days prior
to randomization (6 weeks for Bevacizumab).

2. Radiotherapy ≤ 2 weeks prior to randomization. Patients must have recovered from all
radiotherapy-related toxicities.

3. Major surgical procedure within 4 weeks prior to randomization. Patient must have
recovered from all surgery-related complications.

4. Patients with known CNS metastases (Patients with any clinical signs of CNS
metastases must have a CT or MRI of the brain to rule out CNS metastases in order to
be eligible for participation in the study). Patients who have had brain metastases
treated with radiotherapy or surgically removed with no residual disease confirmed by
imaging; patients should be clinically stable and off corticosteroid treatment at
least 3 weeks prior to randomization).

5. Patients with current diagnosis or a history of another active primary malignancy
(except in situ carcinoma of the cervix, adequately treated non-melanomatous skin
cancers, clinically localized prostate cancer, superficial bladder cancer or other
malignancy treated at least 5 years previously with no evidence of recurrence).

6. Severe or unstable medical conditions such as heart failure, ischemic heart disease,
uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as
well as an ongoing cardiac arrhythmia requiring medication (≥ Grade 2, according to
NCI CTCAE v4.0) or any other significant or unstable concurrent medical illness that
in the opinion of the Investigator would preclude protocol therapy.

7. A history of events such as myocardial infarction, cerebrovascular accident or acute
hepatitis within 3 months of randomization or treatment of a major active infection
within one month of randomization, or any other significant event that in the opinion
of the Investigator would preclude protocol therapy.

8. Planned concomitant participation in another clinical trial of an experimental agent,
vaccine, or device. Concomitant participation in observational studies is acceptable.

9. Female patients who are breastfeeding.

10. Patients previously treated with docetaxel for NSCLC or with known severe
hypersensitivity to taxane therapies.

11. Patients with known and documented EGFR mutation who have not received an EGFR
inhibitor.
We found this trial at
11
sites
Hazard, Kentucky 41701
?
mi
from
Hazard, KY
Click here to add this to my saved trials
Bedford Park, 5042
?
mi
from
Bedford Park,
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
?
mi
from
Joliet, IL
Click here to add this to my saved trials
Knoxville, Tennessee 37909
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
601 E Rollins St
Orlando, Florida 32803
(407) 303-5600
Florida Hospital Florida Hospital is one of the country
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Soynton Beach, Florida
?
mi
from
Soynton Beach, FL
Click here to add this to my saved trials
St. Louis, Missouri 63131
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Winston Salem, North Carolina
?
mi
from
Winston Salem, NC
Click here to add this to my saved trials